Chekler ELP, Kiselyov AS, Ouyang X, Chen X, Pattaropong V, Wang Y, Tuma MC, Doody JF. Discovery of Dual VEGFR-2 and Tubulin Inhibitors with in Vivo Efficacy.
ACS Med Chem Lett 2010;
1:488-92. [PMID:
24900236 PMCID:
PMC4007844 DOI:
10.1021/ml1001568]
[Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2010] [Accepted: 08/14/2010] [Indexed: 12/25/2022] Open
Abstract
In an effort to develop potent, orally bioavailable compounds for the treatment of neoplastic diseases, we developed a class of dual VEGFR-2 kinase and tubulin inhibitors. Targeting the VEGFR receptor kinase and tubulin structure allows for inhibition of both tumor cells and tumor vasculature. Previously, a combination of two compounds, a VEGF receptor tyrosine kinase inhibitor and tubulin agent, was demonstrated to produce an enhanced antitumor response in animal studies. We have reaffirmed their results, with the added benefit that both activities are found in one compound.
Collapse